tiprankstipranks
Advertisement

ENHI - ETF AI Analysis

Compare

Top Page

ENHI

iShares Enhanced International Active ETF (ENHI)

Rating:65Neutral
Price Target:
ENHI, the iShares Enhanced International Active ETF, has a solid overall rating driven mainly by high-quality global leaders like HSBC, Novartis, AstraZeneca, and ASML, which show strong financial performance, positive earnings outlooks, and generally supportive technical trends. Some holdings, such as Shell and Banco Santander, introduce risks through weaker cash flow trends, leverage, or regional challenges, and the fund’s focus on large international financial and healthcare names means investors should be aware of sector and geographic concentration risk.
Positive Factors
Strong Year-To-Date Performance
The ETF has delivered strong gains so far this year, showing solid overall momentum.
Leading Holding With Very Strong Returns
ASML, the fund’s largest position, has shown very strong performance, providing a meaningful boost to the ETF.
Broad International Diversification
The fund is spread across many countries in Europe, Asia, and other regions, which helps reduce the impact of problems in any single market.
Negative Factors
Recent Short-Term Weakness
The ETF has slipped slightly over the past month, which may signal near-term volatility.
Mixed Performance Among Top Holdings
While several major positions are performing well, at least one large holding like AstraZeneca has been weak, which can drag on returns.
Moderate Expense Ratio
The fund’s fee is not extremely high but is also not among the cheapest, which slightly reduces the net return to investors over time.

ENHI vs. SPDR S&P 500 ETF (SPY)

ENHI Summary

The iShares Enhanced International Active ETF (ENHI) is a global stock fund that focuses on companies outside the U.S., mainly larger and mid-sized firms across many countries like Japan, the UK, and France. It doesn’t track a single index, but instead uses data-driven stock picking to try to beat a broad international market. Well-known holdings include ASML and Nestlé. Investors might consider ENHI for international diversification with the potential for a bit more growth than a plain index fund. A key risk is that, as an active fund, its returns can differ a lot from the overall market and may underperform.
How much will it cost me?This ETF has an expense ratio of 0.27%, which means you’ll pay about $2.70 per year for every $1,000 you invest. That’s a bit higher than the average low-cost index ETF because ENHI is actively managed, using data-driven stock selection instead of simply tracking a market index.
What would affect this ETF?This ETF focuses on developed markets outside North America and holds many large financial, industrial, health care, and technology companies, so it could benefit if global growth stays solid, interest rates stabilize or fall, and innovation and consumer demand remain strong in Europe and Asia. On the other hand, it could be hurt by economic slowdowns overseas, banking or regulatory issues affecting its big financial holdings, higher interest rates that pressure stocks broadly, or if its active, data-driven strategy fails to pick the right companies compared with simple index funds.

ENHI Top 10 Holdings

ENHI leans heavily into developed markets outside North America, with a clear tilt toward European financials and health care giants. ASML has been the star of the show, its rising share price giving the fund a strong tech-powered tailwind. Big banks like HSBC and Mitsubishi UFJ are also pulling their weight, adding steady momentum. On the defensive side, Roche, Novartis, and Nestlé are quietly keeping things on track, while AstraZeneca has been losing steam lately and acting as a mild drag rather than a driver.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV3.12%$674.90K€547.84B141.04%
76
Outperform
HSBC Holdings1.64%$355.95K£270.81B71.70%
80
Outperform
Roche Holding AG1.54%$332.78K$348.49B38.80%
73
Outperform
Siemens1.36%$294.63K€215.45B31.61%
74
Outperform
Mitsubishi UFJ Financial Group1.35%$291.56K¥39.93T62.91%
76
Outperform
Novartis AG1.34%$291.05KCHF231.75B34.41%
80
Outperform
AstraZeneca1.31%$283.21K$263.99B3.27%
80
Outperform
Shell (UK)1.23%$266.96K£187.43B24.99%
73
Outperform
Nestlé SA1.14%$246.42KCHF208.38B13.38%
71
Outperform
Banco Santander1.12%$242.79K€180.75B61.54%
73
Outperform

ENHI Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
26.46
Positive
100DMA
200DMA
Market Momentum
MACD
0.17
Negative
RSI
60.14
Neutral
STOCH
91.28
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For ENHI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.66, equal to the 50-day MA of 26.46, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.17 indicates Negative momentum. The RSI at 60.14 is Neutral, neither overbought nor oversold. The STOCH value of 91.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENHI.

ENHI Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$21.65M0.27%
65
Neutral
$87.15M0.55%
66
Neutral
$61.85M0.58%
62
Neutral
$26.66M0.55%
68
Neutral
$21.74M
66
Neutral
$11.52M0.30%
67
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ENHI
iShares Enhanced International Active ETF
27.18
3.25
13.58%
QUIZ
Zacks Quality International ETF
AIVI
WisdomTree International AI Enhanced Value Fund
JIDE
JPMorgan International Dynamic ETF
TACN
T. Rowe Price Active Core International Equity ETF
PQNT
Pictet AI Enhanced International Equity ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement